177 related articles for article (PubMed ID: 15637036)
1. Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease.
Moitra RK; Ledingham JM; Hull RG; McCrae FC; Thomas AL; Shaban R; Mackay KR
Rheumatology (Oxford); 2005 Feb; 44(2):256-7. PubMed ID: 15637036
[No Abstract] [Full Text] [Related]
2. Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?
Pincus T; Sokka T
Rheumatology (Oxford); 2006 May; 45(5):497-9. PubMed ID: 16537578
[No Abstract] [Full Text] [Related]
3. Methotrexate-induced hiccups.
Javot L; Scala-Bertola J; Petitpain N; Trechot P; Pere P; Gillet P
Rheumatology (Oxford); 2011 May; 50(5):989-90. PubMed ID: 21278070
[No Abstract] [Full Text] [Related]
4. Teaching home administration of sub-cutaneous methotrexate.
Livermore P
Paediatr Nurs; 2003 Apr; 15(3):28-32. PubMed ID: 12715587
[No Abstract] [Full Text] [Related]
5. Methotrexate--the anchor drug--an introduction.
Pincus T; Cronstein B; Braun J
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S1-2. PubMed ID: 21044424
[No Abstract] [Full Text] [Related]
6. Shortening infusion times for infliximab administration.
Buch MH; Bryer D; Lindsay S; Rees-Evans B; Fairclough A; Emery P
Rheumatology (Oxford); 2006 Apr; 45(4):485-6. PubMed ID: 16352636
[No Abstract] [Full Text] [Related]
7. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate.
Rozin A; Schapira D; Balbir-Gurman A; Braun-Moscovici Y; Markovits D; Militianu D; Nahir MA
Ann Rheum Dis; 2002 Aug; 61(8):756-7. PubMed ID: 12117691
[No Abstract] [Full Text] [Related]
8. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.
Pincus T; Furer V; Sokka T
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S68-79. PubMed ID: 21044437
[TBL] [Abstract][Full Text] [Related]
9. Does low-dose methotrexate deserve more respect from clinicians?
Luu B; Rodway GW
JAAPA; 2017 May; 30(5):12-15. PubMed ID: 28441215
[TBL] [Abstract][Full Text] [Related]
10. [Methotrexate: mainstay of rheumatoid arthritis treatment].
Jacobs JW; Bijlsma JW
Ned Tijdschr Geneeskd; 2009; 153():A879. PubMed ID: 19785862
[TBL] [Abstract][Full Text] [Related]
11. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
Raghu P; Grover PS; Kumar A
Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
[No Abstract] [Full Text] [Related]
12. TPMT testing in rheumatology: any better than routine monitoring?
Payne K; Newman W; Fargher E; Tricker K; Bruce IN; Ollier WE
Rheumatology (Oxford); 2007 May; 46(5):727-9. PubMed ID: 17255139
[No Abstract] [Full Text] [Related]
13. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF;
Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349
[No Abstract] [Full Text] [Related]
14. The use of methotrexate in childhood rheumatic diseases.
Wallace CA
Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564
[No Abstract] [Full Text] [Related]
15. An update on methotrexate.
Braun J; Rau R
Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
[TBL] [Abstract][Full Text] [Related]
16. [The use of methotrexate in rheumatology: results and prospects].
Nasonov EL
Klin Med (Mosk); 1996; 74(5):10-5. PubMed ID: 8999172
[No Abstract] [Full Text] [Related]
17. Missing the obvious.
Nuenninghoff DM
J Rheumatol; 2009 Aug; 36(8):1833; author reply 1833. PubMed ID: 19671823
[No Abstract] [Full Text] [Related]
18. Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA.
Rau R
J Rheumatol; 2005 Jul; 32(7):1412; author reply 1412-3. PubMed ID: 15996092
[No Abstract] [Full Text] [Related]
19. Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy.
Thornton C; Ong V; Ward J; Kennedy N; Steuer A
Rheumatology (Oxford); 2008 Sep; 47(9):1438; author reply 1438. PubMed ID: 18617550
[No Abstract] [Full Text] [Related]
20. Toward a better understanding of methotrexate.
Kremer JM
Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
